Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | FABP7 | O15540 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702199 | 1.00 | CA12 (0.61) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL422837 | 0.98 | CA12 (0.59) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2773503 | 0.98 | CA12 (0.59) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL29057819 | 0.98 | CA12 (0.59) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL23878485 | 0.98 | CA12 (0.59) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL23878397 | 0.98 | CA12 (0.59) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL2017048 | 0.98 | CA12 (0.59) | CA12CA1CA2CA9ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL23878422 | 0.98 | CA12 (0.59) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL11767145 | 0.98 | CA12 (0.59) | CA12CA1CA2CA9ALDH1A1 | |
| Benzene SCHEMBL29116606 | 0.98 | CA12 (0.59) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107141241-B | Copper-sulphide ores flotation collector and its preparation method and application | 九江学院 | 2019-04-30 | — | — | CN | claimed |
| WO-2025050647-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 晟迪生物医药(苏州)有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-20240269093-A1 | USE OF METFORMIN AND ANALOGS THEREOF TO REDUCE RAN PROTEIN LEVELS IN THE TREATMENT OF NEUROLOGICAL DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-4288110-A2 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | Biohaven Therapeutics Ltd. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11731928-B2 | Co-crystals of sodium benzoate and uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2023-08-22 | — | — | US | disclosed |
| EP-4185599-A2 | STAPLED PEPTIDES AND METHODS THEREOF | Fog Pharmaceuticals, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-4185284-A1 | AMINO ACIDS | Fog Pharmaceuticals, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-4121082-A1 | HELICAL STAPLED PEPTIDES AND USES THEREOF | Fog Pharmaceuticals, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2023288257-A2 | BIOCATALYTIC COUPLING REACTIONS TOWARD REGIOSELECTIVELY ENRICHED SUBSTITUTED PYRAZINES | CONAGEN INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-1238762-A | Piperidine compounds | GILEAD SCIENCES INC (US) | 1999-12-15 | — | — | CN | disclosed |
| CN-1177955-A | Process for preparing retroviral protease inhibitor intermediates | SEARLE & CO (US) | 1998-04-01 | — | — | CN | disclosed |
| EP-0804410-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0730570-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| US-4108854-A | Process for preparing substituted glycines | SMITHKLINE CORPORATION (US) | 1978-08-22 | — | — | US | disclosed |
| US-4094895-A | Process for preparation of O-(substituted)benzyl thiocarbamates | STAUFFER CHEMICAL COMPANY (US) | 1978-06-13 | — | — | US | disclosed |
| US-4062971-A | S-alkyl carbonimidothioates and their use as aphicides | STAUFFER CHEMICAL COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
| US-3997584-A | Substituted glycines and intermediates thereof | SMITHKLINE CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
| US-3994954-A | Process for preparing substituted glycines | SMITHKLINE CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731928-B2 | Co-crystals of sodium benzoate and uses thereof | SLC5A1, PC, SLC5A2 | CA12 1968/4885CA1 930/4885CA2 1326/4885 |
| US-20240269093-A1 | USE OF METFORMIN AND ANALOGS THEREOF TO REDUCE RAN PROTEIN LEVELS IN THE TREATMENT OF NEUROLOGICAL DISORDERS | EIF4E, EIF4EBP1, GRN | CA12 4173/4885CA1 3933/4885CA2 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.